HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.

Abstract
Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity such as gefitinib and erlotinib. Responses to TK inhibitors in the absence of EGFR gene mutation for BAC patients have not been reported. A case of a patient with BAC refractory to chemotherapy who responded to gefitinib in the absence of EGFR gene mutations is reported. Tyrosine kinase inhibitors may have a role in BAC in the absence of EGFR gene mutations. Additional studies on other molecular alterations of the EGFR family members are needed to better predict response to these agents.
AuthorsLucia Taja-Chayeb, Myrna Candelaria, Rocio Brom, Catalina Trejo-Becerril, Fabian Meza, Alfonso Duenas-Gonzalez
JournalLung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 50 Issue 2 Pg. 259-63 (Nov 2005) ISSN: 0169-5002 [Print] Ireland
PMID16009451 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Quinazolines
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Gefitinib
Topics
  • Adenocarcinoma, Bronchiolo-Alveolar (drug therapy, genetics)
  • Aged
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • DNA Mutational Analysis
  • Drug Resistance, Neoplasm
  • ErbB Receptors (genetics)
  • Female
  • Gefitinib
  • Humans
  • Lung Neoplasms (drug therapy, genetics)
  • Protein-Tyrosine Kinases (genetics)
  • Quinazolines (pharmacology, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: